Bellevue Group Ag Agios Pharmaceuticals, Inc. Transaction History

Bellevue Group Ag

$4.39 Billion
Q2 2025

A detailed history of Bellevue Group Ag transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 3,590,150 shares of AGIO stock, worth $127 Million. This represents 2.72% of its overall portfolio holdings.

Number of Shares

3,590,150

Previous 3,515,150 2.13%

Holding current value

$127 Million

Previous $103 Million 15.94%

% of portfolio

2.72%

Previous 2.39%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$24.53 - $35.75 $1.84 Million - $2.68 Million	75,000 Added 2.13%	3,590,150 $119 Million
Q4 2024 Feb 14, 2025	SELL	$32.86 - $61.64 $7.25 Million - $13.6 Million	-220,765 Reduced 5.91%	3,515,150 $116 Million
Q3 2024 Nov 14, 2024	SELL	$41.19 - $49.72 $5.92 Million - $7.14 Million	-143,633 Reduced 3.7%	3,735,915 $166 Million
Q2 2024 Aug 14, 2024	SELL	$27.55 - $48.83 $3.48 Million - $6.17 Million	-126,452 Reduced 3.16%	3,879,548 $167 Million
Q1 2024 May 15, 2024	SELL	$21.32 - $34.81 $106,600 - $174,050	-5,000 Reduced 0.12%	4,006,000 $117 Million
Q4 2023 Feb 14, 2024	SELL	$19.97 - $24.53 $49,925 - $61,325	-2,500 Reduced 0.06%	4,011,000 $89.3 Million
Q1 2023 May 15, 2023	SELL	$21.74 - $30.93 $941,168 - $1.34 Million	-43,292 Reduced 1.07%	4,013,500 $92.2 Million
Q4 2022 Feb 14, 2023	SELL	$24.81 - $31.52 $49,620 - $63,040	-2,000 Reduced 0.05%	4,056,792 $114 Million
Q3 2022 Nov 14, 2022	SELL	$19.51 - $34.14 $78,040 - $136,560	-4,000 Reduced 0.1%	4,058,792 $115 Million
Q2 2022 Aug 11, 2022	SELL	$17.06 - $31.42 $1.13 Million - $2.09 Million	-66,500 Reduced 1.61%	4,062,792 $90.1 Million
Q1 2022 May 13, 2022	SELL	$26.68 - $34.81 $5.87 Million - $7.66 Million	-220,000 Reduced 5.06%	4,129,292 $120 Million
Q4 2021 Feb 10, 2022	BUY	$29.58 - $49.78 $215,934 - $363,394	7,300 Added 0.17%	4,349,292 $143 Million
Q3 2021 Nov 12, 2021	SELL	$41.92 - $58.18 $461,120 - $639,980	-11,000 Reduced 0.25%	4,341,992 $200 Million
Q2 2021 Aug 12, 2021	SELL	$52.06 - $61.27 $9.58 Million - $11.3 Million	-184,100 Reduced 4.06%	4,352,992 $240 Million
Q1 2021 May 12, 2021	BUY	$44.23 - $57.5 $14.9 Million - $19.3 Million	336,090 Added 8.0%	4,537,092 $234 Million
Q4 2020 Feb 16, 2021	BUY	$33.21 - $46.54 $1.66 Million - $2.33 Million	50,000 Added 1.2%	4,201,002 $182 Million
Q3 2020 Nov 16, 2020	BUY	$33.87 - $55.93 $4.32 Million - $7.13 Million	127,429 Added 3.17%	4,151,002 $145 Million
Q2 2020 Aug 13, 2020	BUY	$34.45 - $53.48 $4.07 Million - $6.32 Million	118,129 Added 3.02%	4,023,573 $215 Million
Q1 2020 May 14, 2020	SELL	$31.52 - $53.81 $614,955 - $1.05 Million	-19,510 Reduced 0.5%	3,905,444 $139 Million
Q4 2019 Feb 14, 2020	BUY	$30.08 - $50.59 $10.6 Million - $17.9 Million	353,400 Added 9.89%	3,924,954 $187 Million
Q3 2019 Nov 14, 2019	BUY	$32.4 - $49.58 $14.4 Million - $22 Million	443,420 Added 14.18%	3,571,554 $116 Million
Q2 2019 Aug 14, 2019	BUY	$46.17 - $68.1 $144 Million - $213 Million	3,128,134 New	3,128,134 $156 Million
Q4 2018 Feb 12, 2019	SELL	$42.73 - $76.53 $848,660 - $1.52 Million	-19,861 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$71.67 - $91.95 $641,446 - $822,952	-8,950 Reduced 31.06%	19,861 $1.53 Million
Q2 2018 Aug 07, 2018	SELL	$73.22 - $99.55 $841,224 - $1.14 Million	-11,489 Reduced 28.51%	28,811 $2.43 Million
Q1 2018 May 09, 2018	SELL	$59.83 - $86.53 $35,898 - $51,918	-600 Reduced 1.47%	40,300 $3.3 Million
Q4 2017 Feb 14, 2018	SELL	$52.12 - $72.33 $213,692 - $296,553	-4,100 Reduced 9.11%	40,900 $2.34 Million
Q2 2017 Aug 14, 2017	BUY	N/A	45,000	45,000 $2.32 Million

Others Institutions Holding AGIO

# of Institutions

234

Shares Held

61.8M

Call Options Held

297K

Put Options Held

235K

View Full List

About AGIOS PHARMACEUTICALS, INC.

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.94B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

More about AGIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Agios Pharmaceuticals, Inc. Transaction History